

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4695534

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
ORBIMED ROYALTY OPPORTUNITIES II, LP	11/17/2017

RECEIVING PARTY DATA

Name:	RECRO GAINESVILLE LLC (F/K/A RECRO TECHNOLOGY LLC)
Street Address:	1300 GOULD DRIVE
City:	GAINESVILLE
State/Country:	GEORGIA
Postal Code:	30504

PROPERTY NUMBERS Total: 17

Property Type	Number
Patent Number:	5834025
Patent Number:	RE41884
Patent Number:	7459283
Patent Number:	8323641
Patent Number:	8652464
Patent Number:	8512727
Patent Number:	8992973
Patent Number:	6908626
Patent Number:	6228398
Patent Number:	6902742
Patent Number:	6730325
Patent Number:	6793936
Patent Number:	9308177
Application Number:	14182097
Application Number:	13941076
Application Number:	11372857
Application Number:	10827689

CORRESPONDENCE DATA

Fax Number: (704)378-2057

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

PATENT

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7043312359
Email: cindigraser@mvalaw.com, vangambrell@mvalaw.com
Correspondent Name: MOORE & VAN ALLEN PLLC
Address Line 1: 3015 CARRINGTON MILL BOULEVARD, STE 400
Address Line 2: POST OFFICE BOX 13706
Address Line 4: RESEARCH TRIANGLE PA, NORTH CAROLINA 27709

ATTORNEY DOCKET NUMBER:	036251.000040
NAME OF SUBMITTER:	PETER B. STEWART
SIGNATURE:	/Peter B. Stewart/
DATE SIGNED:	11/17/2017

Total Attachments: 16

- source=RecroGainesville-Release-Patent-Security-Interest#page1.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page2.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page3.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page4.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page5.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page6.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page7.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page8.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page9.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page10.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page11.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page12.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page13.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page14.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page15.tif
- source=RecroGainesville-Release-Patent-Security-Interest#page16.tif

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “**Release**”) is made and effective as of November 17, 2017 and granted by ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the “**Lender**”), as lender under the Credit Agreement referred to below, in favor of RECRO GAINESVILLE LLC (f/k/a RECRO TECHNOLOGY LLC), a Massachusetts limited liability company (the “**Grantor**”) and its successors, assigns and legal representatives.

WHEREAS, pursuant to that certain Credit Agreement, dated as of March 7, 2015 (as amended, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), by and between the Grantor and the Lender, the Grantor executed and delivered to the Lender (i) that certain Pledge and Security Agreement, dated as of April 10, 2015 (the “**Pledge & Security Agreement**”), by and among Recro Pharma, Inc., a Pennsylvania corporation, the Grantor and the Lender and (ii) that certain Patent Security Agreement, dated as of April 10, 2015 (the “**Patent Security Agreement**” and together with the Pledge & Security Agreement, the “**Security Agreements**”);

WHEREAS, pursuant to the Security Agreements, the Grantor pledged and granted to the Lender for its benefit a security interest in and to all of the right, title and interest of such Grantor in, to and under the Patent Collateral (as defined in the Patent Security Agreement);

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office at Reel 035403, Frame 0288 on April 14, 2015; and

WHEREAS, the Lender wishes to provide a document evidencing the release, relinquishment and discharge of its security interest in the Patent Collateral.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lender hereby states as follows:

1. Release of Security Interest. The Lender, on behalf of itself and its successors, legal representatives and assigns, hereby terminates the Patent Security Agreement and terminates, releases and discharges any and all security interests that it has pursuant to the Patent Security Agreement in any and all right, title and interest of the Grantor, and reassigns to the Grantor any and all right, title and interest that it may have, in, to and under the Patent Collateral (including the patents and patent licenses listed on **Schedule 1** and **Schedule 2** hereto).
2. Authorization. The Lender hereby authorizes and requests the United States Patent and Trademark Office and any other applicable government officer to record this Release.

3. Further Assurances. The Lender agrees, at the Grantor's expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.

3. Execution in Counterparts. This Release may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which counterparts taken together shall be deemed to constitute one and the same instrument. Telecopied signatures hereto shall be of the same force and effect as an original of a manually signed copy.

4. Governing Law. **THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE UNITED STATES AND THE STATE OF NEW YORK WITHOUT REFERENCE TO ANY CHOICE OR CONFLICT OF LAW DOCTRINE THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.**

[Signature Page Follows]

IN WITNESS WHEREOF, the Lender has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

ORBIMED ROYALTY OPPORTUNITIES II, LP
as the Lender

By OrbiMed ROF II LLC,
its General Partner

By OrbiMed Advisors LLC,
its Managing Member

By: W. Carter Neild
Name: W. Carter Neild
Title: Member

SCHEDULE 1

Issued Patents

Country	Patent No.	Issue Date	Inventors	Title
US	5,834,025	10-Nov-1998	Lawrence de Garavilla, Elaine M. Liversidge, Gary G. Liversidge	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US	RE41,884 E	26-Oct-2010	Lawrence de Garavilla, Elaine M. Liversidge, Gary G. Liversidge	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
CA	2,232,879	02-Mar-2004	Lawrence de Garavilla, Elaine M. Liversidge, Gary G. Liversidge	Reduction Of Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions
US	7,459,283	02-Dec-2008	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
US	8,323,641	Dec 4, 2012	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
US	8,652,464	Feb 18, 2014	Christian F. Wertz, Niels P. Ryde	Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer
Austria	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Belgium	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Bulgaria	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Canada	2,475,092	01-May-2012	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer

Country	Patent No.	Issue Date	Inventors	Title
Czech Republic	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Denmark	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
European Patent Convention	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Finland	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
France	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Germany	60332212	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Greece	3072191	11-Jun-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Hungary	E008527	28-Dec-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Ireland	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Italy	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Liechtenstein	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Netherlands	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Portugal	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Slovakia	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer

Country	Patent No.	Issue Date	Inventors	Title
Spain	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Sweden	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Switzerland	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
United Kingdom	EP1471887	21-Apr-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
Japan	4,598,399	01-Oct-2010	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
US	8,512,727	20-Aug-2013	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
CA	2,517,679	10-Apr-2012	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
JP	4,891,774	11-Dec-2011	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
JP	5,548,092	11-Dec-2011	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
HU	E005977	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations

Country	Patent No.	Issue Date	Inventors	Title
BE	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
FR	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
DE	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
IE	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
IT	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
LI	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
CH	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
GB	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations

Country	Patent No.	Issue Date	Inventors	Title
ES	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
EPC	EP1617816	13-May-2009	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
US	8,992,973	31-Mar-2015	Gurvinder Singh Rekhi; Richard Sidwell; Sharon Hamm	Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride
US	6,908,626	21-Jun-2005	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
CA	2,463,495	24-May-2011	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
DE	60222160.9	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
AT	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
BE	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
BU	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
CY	EP1443912	07-May-2010	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics

Country	Patent No.	Issue Date	Inventors	Title
CZ	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
DK	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
EE	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
EPO	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
FI	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
FR	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
GR	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
IE	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
IT	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
LU	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics

Country	Patent No.	Issue Date	Inventors	Title
MC	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
NL	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
PT	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
SK	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
ES	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
SE	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
CH	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
TR	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
GB	EP1443912	29-Aug-2007	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
US	6,228,398	08-May-2001	John G. Devane; Paul Stark; Niall M.M. Fanning	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION

Country	Patent No.	Issue Date	Inventors	Title
US	6,902,742	07-Jun-2005	John G. Devane; Paul Stark; Niall M.M. Fanning; Gurvinder Singh Rekhi	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
US	6,730,325	04-May-2004	John G. Devane; Paul Stark; Niall M.M. Fanning; Gurvinder Singh Rekhi	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
US	6,793,936	21-SEP-2004	John G. Devane; Paul Stark; Niall M.M. Fanning	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
CA	2,348,871	14-Apr-2009	John G. Devane; Paul Stark; Niall M.M. Fanning	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
US	9,308,177	12-Apr-2016	Gurvinder Singh Rekhi; Richard Sidwell; Sharon Hamm	Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

Pending Patent Applications

Country	Application No.	Filing Date	Inventors	Title
EPO	10181619.7	29-Sep-2010	Lawrence de Garavilla, Elaine M. Liversidge, Gary G. Liversidge	Reduction of intravenously administered nanoparticulate- formulation-induced adverse physiological reactions
US	14/182,097	17 Feb 2014	Christian F. Wertz, Niels P. Ryde	Nanoparticulate compositions having lysozyme as a surface stabilizer
US	13/941,076	12-Jul-2013	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations

Country	Application No.	Filing Date	Inventors	Title
EPO	08006465.2	27-Feb-2004	Eugene R. Cooper; Tuula Ryde; John Pruitt, Laura Kline	Nanoparticulate Meloxicam Formulations
CA	2,627,951	26-Oct-2006	Gurvinder Singh Rekhi; Richard Sidwell; Sharon Hamm	Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride
EPO	06826637.8	26-Oct-2006	Gurvinder Singh Rekhi; Richard Sidwell; Sharon Hamm	Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride
JP	2013-126534	11-Oct-2002	Eugene R. Cooper; Stephen B. Ruddy	Compositions Having A Combination Of Immediate Release And Controlled Release Characteristics
US	11/372,857	10-Mar-2006	John G. Devane; Paul Stark; Niall M. M. Fanning; Gurvinder Singh Rekhi; Scott A. Jenkins; Gary Liversidge	Multiparticulate Modified Release Composition
US	10/827,689	19-Apr-2004	John G. Devane; Paul Stark; Niall M. M. Fanning; Gurvinder Singh Rekhi; Scott A. Jenkins;	Multiparticulate Modified Release Composition

Patent Applications in Preparation

<u>Country</u>	<u>Docket No.</u>	<u>Expected Filing Date</u>	<u>Inventor(s)</u>	<u>Title</u>
none				

Patent Licenses

<u>Territory</u>	<u>Licensor</u>	<u>Licensee</u>	<u>Effective Date</u>	<u>Expiration Date</u>	<u>Subject Matter</u>
Worldwide	Alkermes Pharma Ireland Limited	RECRO TECHNOLOGY LLC	TBD	TBD	Controlled Release, Abuse Deterrent and Nanocrystal technology

SCHEDULE 2

Issued Patents

<u>Country</u>	<u>Serial No.</u>	<u>Issue Date</u>	<u>Inventors</u>	<u>Title</u>
US	9,452,163	27-Sep-2016		Abuse resistant pharmaceutical compositions
US	9,486,451	8-Nov-2016		Abuse resistant pharmaceutical compositions
US	9,713,611	25-Jul-2017		Abuse resistant pharmaceutical compositions
US	9,463,166	11-Oct-2016		Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

Pending Patent Applications

<u>Country</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventors</u>	<u>Title</u>
US	15/626,268	19-Jun-2017		Abuse resistant pharmaceutical compositions
US	15/193,514	27-Jun-2016		Multiparticulate Modified Release Composition
PCT	PCT/IB2015/056993	11-Sep-2015		Abuse resistant pharmaceutical compositions
EP	2015771283	11-Sep-2015		ABUSE RESISTANT PHARMACEUTICAL COMPOSITIONS
JP	2017-534015	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC

<u>Country</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventors</u>	<u>Title</u>
				AL COMPOSITIONS
CA	2870380	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
AU	2015313785	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
BR	1120170048825	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
CN	201580054813	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
CR	2017-0142	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
IL	251011	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
MX	20173082	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
NZ	730882	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
RU	2017112301	11-Sep-2015		ABUSE

<u>Country</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventors</u>	<u>Title</u>
				RESISTANT PHARMACEUTIC AL COMPOSITIONS
SG	11201701845	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
ZA	2017/01721	11-Sep-2015		ABUSE RESISTANT PHARMACEUTIC AL COMPOSITIONS
US	15/257,653	6-Sep-2016		Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride